Welcome to our dedicated page for Spruce Biosciences SEC filings (Ticker: SPRB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Spruce Biosciences, Inc. (SPRB) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, along with AI-powered summaries to help interpret complex documents. Spruce is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, and its filings offer detailed insight into clinical programs, financing arrangements, and corporate governance.
Investors can review current reports on Form 8-K that describe material events such as the company’s loan and security agreement with Avenue Venture Opportunities Fund II, L.P. for up to $50.0 million in term loans tied to regulatory and commercial milestones for tralesinidase alfa enzyme replacement therapy (TA-ERT) in Sanfilippo Syndrome Type B (MPS IIIB). Other 8-K filings cover a private placement of common stock and pre-funded warrants with institutional investors, conditional Nasdaq approval and resumption of trading on the Nasdaq Capital Market, reverse stock split implementation, quarterly financial results, and changes in the composition of the board of directors.
Spruce’s filings also detail equity and compensation structures, including option repricing actions for certain outstanding stock options and the non-employee director compensation policy under which new directors such as Keli Walbert receive stock option grants and cash retainers. These documents help clarify how the company uses equity incentives and capital structure adjustments to support its development and listing objectives.
Through this page, you can monitor Spruce’s annual reports (Form 10-K) and quarterly reports (Form 10-Q) when filed, which expand on risk factors, financial statements, and management’s discussion of operations. Form 4 and related insider transaction reports, when available, can be used to track trading activity by officers and directors. Stock Titan’s AI tools summarize lengthy filings, highlight key terms in financing agreements, and surface important disclosures related to TA-ERT’s development path, Nasdaq listing status, and the company’s liquidity and capital resources.
Spruce Biosciences entered into an underwriting agreement for a public sale of 1,150,000 shares of common stock at $50.00 per share and pre-funded warrants to purchase 50,000 shares at $49.99 each. Underwriters also exercised a 30-day option to buy 180,000 additional shares at the public price.
The transaction is expected to generate approximately $69.0 million in gross proceeds before fees, providing new capital to the company. The pre-funded warrants carry a $0.01 exercise price and limits that generally cap any holder’s beneficial ownership at 4.99%, with the ability to elect up to 9.99% with advance notice.
Spruce Biosciences is offering 1,150,000 shares of common stock and pre-funded warrants to purchase 50,000 shares. The offering prices are $50.00 per share and $49.99 per pre-funded warrant, with expected gross proceeds of $59,999,500 before underwriting discounts. Net proceeds are estimated at approximately $55.9 million, intended to fund pre-commercial and launch activities, planned clinical trials, working capital, capital expenditures and general corporate purposes.
The pre-funded warrants have a $0.01 exercise price, do not expire, are not expected to be listed, and include beneficial-ownership exercise limits (4.99% default, electable to 9.99%). The underwriters have a 30-day option to purchase up to 180,000 additional shares.
Spruce Biosciences, Inc. is offering shares of its common stock and pre-funded warrants to purchase common stock in a registered primary offering under its shelf registration. The pre-funded warrants have a $0.01 exercise price and do not expire; they are offered in lieu of common stock to certain investors. The prospectus discloses liquidity limits for the pre-funded warrants (no exchange listing expected), an ownership exercise limitation (4.99% default, electable up to 9.99%), and that net proceeds will be used for pre-commercial and launch activities, planned clinical trials, working capital and general corporate purposes. The document also states key capitalization figures as of December 31, 2025 and references an ATM Program with capacity up to $75.0 million.
Spruce Biosciences, Inc. is offering shares of its common stock and pre-funded warrants to purchase common stock in a registered primary offering under its shelf registration. The pre-funded warrants have a $0.01 exercise price and do not expire; they are offered in lieu of common stock to certain investors. The prospectus discloses liquidity limits for the pre-funded warrants (no exchange listing expected), an ownership exercise limitation (4.99% default, electable up to 9.99%), and that net proceeds will be used for pre-commercial and launch activities, planned clinical trials, working capital and general corporate purposes. The document also states key capitalization figures as of December 31, 2025 and references an ATM Program with capacity up to $75.0 million.
Spruce Biosciences, Inc. will hold its 2026 virtual annual meeting of stockholders on May 21, 2026 at 10:00 a.m. Pacific Time. Holders of 1,372,278 shares of common stock as of March 24, 2026 may vote online.
Stockholders will vote on electing three Class III directors to terms ending at the 2029 annual meeting, ratifying BDO USA, P.C. as independent auditor for 2026, approving on an advisory basis executive compensation, and choosing how often future advisory pay votes should occur. The filing also explains a previously effected 1-for-75 reverse stock split, board independence and structure, committee memberships, ownership of major holders and insiders, and key governance policies, including an insider trading policy and clawback framework.
Spruce Biosciences terminated its collaboration and license agreement with Kaken Pharmaceutical for tildacerfont in Japan, effective March 31, 2026, eliminating rights to up to approximately $65.0 million in potential milestone payments and future royalties, though no early termination penalties apply.
The company reported full-year 2025 net loss of $39.0 million, improved from $53.0 million in 2024, as total operating expenses fell to $36.5 million from $61.1 million, driven by ending tildacerfont development and focusing on tralesinidase alfa enzyme replacement therapy (TA-ERT) for Sanfilippo syndrome type B.
Cash and cash equivalents were $48.9 million as of December 31, 2025, and a loan facility with Avenue Capital provides up to $50 million, including an initial funded tranche of $15 million. Positive FDA Type B meetings support a planned biologics license application for TA-ERT in the fourth quarter of 2026, and new commercial and development leaders were added ahead of a potential launch.
Hooks Corwin Dale reported acquisition or exercise transactions in this Form 4 filing.
Spruce Biosciences, Inc. reported that Chief Commercial Officer Corwin Dale Hooks received a grant of 11,000 Restricted Stock Units. Each RSU represents a contingent right to one share of common stock. The units vest in four equal 25% installments each March 15 from 2027 through 2030, conditioned on continued service.
Hooks Corwin Dale reported acquisition or exercise transactions in this Form 4 filing.
Spruce Biosciences, Inc. reported that Chief Commercial Officer Corwin Dale Hooks received a grant of 11,000 Restricted Stock Units. Each RSU represents a contingent right to one share of common stock. The units vest in four equal 25% installments each March 15 from 2027 through 2030, conditioned on continued service.
SPRUCE BIOSCIENCES, INC. filed a Form 3 identifying Corwin Dale Hooks, its Chief Commercial Officer, as a reporting person. The filing lists no transactions, indicating that no purchases, sales, acquisitions, or dispositions of SPRB securities are reported in this initial ownership statement.
SPRUCE BIOSCIENCES, INC. filed a Form 3 identifying Corwin Dale Hooks, its Chief Commercial Officer, as a reporting person. The filing lists no transactions, indicating that no purchases, sales, acquisitions, or dispositions of SPRB securities are reported in this initial ownership statement.
Spruce Biosciences is offering up to $75.0 million of common stock under an at-the-market sales agreement with Jefferies LLC. The sales may occur from time to time on the Nasdaq Capital Market and other trading venues, with Jefferies acting as agent and receiving a 3.0% commission on gross proceeds.
The prospectus supplement states proceeds may be used to fund clinical programs and for general corporate purposes, including working capital, operating expenses and capital expenditures. The assumed illustrative offering price referenced is $55.87 per share (last reported sale price on March 6, 2026), and the filing notes potential dilution and variability in the number and timing of shares sold.
Spruce Biosciences is offering up to $75.0 million of common stock under an at-the-market sales agreement with Jefferies LLC. The sales may occur from time to time on the Nasdaq Capital Market and other trading venues, with Jefferies acting as agent and receiving a 3.0% commission on gross proceeds.
The prospectus supplement states proceeds may be used to fund clinical programs and for general corporate purposes, including working capital, operating expenses and capital expenditures. The assumed illustrative offering price referenced is $55.87 per share (last reported sale price on March 6, 2026), and the filing notes potential dilution and variability in the number and timing of shares sold.
Spruce Biosciences, Inc. entered a new Open Market Sale agreement with Jefferies that allows at‑the‑market issuances of common stock under its existing shelf registration, replacing a 2022 sales agreement. The company also highlighted progress for tralesinidase alfa enzyme replacement therapy (TA‑ERT) for Sanfilippo syndrome type B following positive FDA Type B meetings and is preparing a biologics license application targeted for the fourth quarter of 2026.
For 2025, Spruce reported cash and cash equivalents of $48.9 million as of December 31, 2025, excluding $15.0 million of loan proceeds received in January 2026, and expects this cash to fund operations into early 2027. Research and development expenses fell to $19.5 million from $46.4 million in 2024, while general and administrative expenses rose to $17.0 million from $14.6 million. Total operating expenses declined to $36.5 million from $61.1 million, and net loss narrowed to $39.0 million from $53.0 million.
Spruce secured a growth capital loan facility of up to $50 million from Avenue Capital Group, including an initial fully funded $15 million tranche and three additional tranches subject to conditions. The company appointed Corwin Dale Hooks as Chief Commercial Officer with a $480,000 base salary, target bonus up to 40% of salary, and an inducement restricted stock unit grant for 11,000 shares vesting over four years to support potential commercialization of TA‑ERT.
Spruce Biosciences, Inc. entered a new Open Market Sale agreement with Jefferies that allows at‑the‑market issuances of common stock under its existing shelf registration, replacing a 2022 sales agreement. The company also highlighted progress for tralesinidase alfa enzyme replacement therapy (TA‑ERT) for Sanfilippo syndrome type B following positive FDA Type B meetings and is preparing a biologics license application targeted for the fourth quarter of 2026.
For 2025, Spruce reported cash and cash equivalents of $48.9 million as of December 31, 2025, excluding $15.0 million of loan proceeds received in January 2026, and expects this cash to fund operations into early 2027. Research and development expenses fell to $19.5 million from $46.4 million in 2024, while general and administrative expenses rose to $17.0 million from $14.6 million. Total operating expenses declined to $36.5 million from $61.1 million, and net loss narrowed to $39.0 million from $53.0 million.
Spruce secured a growth capital loan facility of up to $50 million from Avenue Capital Group, including an initial fully funded $15 million tranche and three additional tranches subject to conditions. The company appointed Corwin Dale Hooks as Chief Commercial Officer with a $480,000 base salary, target bonus up to 40% of salary, and an inducement restricted stock unit grant for 11,000 shares vesting over four years to support potential commercialization of TA‑ERT.